论文部分内容阅读
近年来,随着抗生素的广泛应用,细菌对其耐药性有逐年增长的趋势。例如,常见病原菌对氨苄西林的耐药率达70％以上。产生细菌耐药性的一个重要因素是细菌产β-内酰胺酶,它可使氨苄西林被水解并失去抗菌活性。舒巴坦(Subactam)系β-内酰胺酶抑制剂,与氨苄西林联合可增强后者的抗菌作用,并扩大抗菌谱;对葡萄球菌(不包括MRSA)、部分不动杆菌及厌氧菌也具抗菌活性。该复合剂在国外于80年代初已用于临床治疗各系统感染,有效率达90％以上。在国内,舒巴坦钠及其与氨苄西林的复合制剂(舒氨新)首先由上海第四制药厂于1990年制成。本文报道1990年1～12月在我院进行该药临床验证的结果。
In recent years, with the widespread use of antibiotics, bacterial resistance to it has a trend of increasing year by year. For example, common pathogenic bacteria ampicillin resistance rate of more than 70%. An important factor in the development of bacterial resistance is the production of beta-lactamases in bacteria that hydrolyse ampicillin and lose antibacterial activity. Subactam, a β-lactamase inhibitor, combined with ampicillin enhances the antibacterial activity of the latter and broadens the antimicrobial spectrum. It also inhibits staphylococci (excluding MRSA), part of Acinetobacter and anaerobic bacteria With antibacterial activity. The complex in foreign countries in the early 80s have been used for clinical treatment of systemic infections, the effective rate of 90% or more. In China, sulbactam sodium and its combination with ampicillin (samoam) were first made by Shanghai No. 4 Pharmaceutical Factory in 1990. This article reports from January 1990 to December 1990 in our hospital clinical validation of the results.